Clinical Trial: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Article

This clinical trial will determine if ketotifen/naphazoline is an effective treatment for acute allergic conjunctivitis.

Click here to access this third party resource:

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Study Type: Interventional

Age/Gender Requirements: 6 years+ (male/female)

Sponsor: Bausch & Lomb, Inc.

Purpose: To determine the safety and efficacy of ketotifen/naphazoline ophthalmic solution “compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.”

Related Videos
Elna Saah, MD: Unraveling the Current Landscape of Sickle Cell Disease | Image Credit: Twitter
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Sunny Rai, PhD: “I” Language Markers Do Not Detect Depression in Black Individuals
© 2024 MJH Life Sciences

All rights reserved.